Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon added to entecavir in entecavir-experienced HBeAg-positive chronic hepatitis B
ChiCTR-IPR-17012055Phase 4Not yet recruiting
- Sponsor
- Shanghai Public Health Clinical Center
- Start
- Sep 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pegylated interferon alpha and entecavir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Shanghai Public Health Clinical Center. Primary endpoint: HBeAg seroconversion rate. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
pegylated interferon alphaentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR-IPR-17012055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012055.